RxDoctor Payments Data

Omar Ortiz-Alvarado, MD

Urology · Coral Springs, FLNPI 1770780017

Payments from drug & device makers

$11,672in general payments, 2019–2025

Across 451 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Axonics, Inc.$1K
  • Myriad Genetic Laboratories, Inc.$905
  • Boston Scientific$805
  • Endo Pharmaceuticals Inc.$776
  • Procept Biorobotics Corporation$690
  • plus $6K from 49 others

What the payments were for

  • Travel & lodging$1,38312%
  • Food & beverage$9,89085%
  • Education$3983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,672 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$96,789
Medicare patients
170
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide21$292,356
Lupron DepotLeuprolide Acetate20$183,077
ErleadaApalutamide12$167,548
MyrbetriqMirabegron206$129,123
GemtesaVibegron120$81,666
EligardLeuprolide Acetate28$53,097
OrgovyxRelugolix12$32,784
Tamsulosin Hcl900$7,864
Estradiol109$7,431
Finasteride670$6,639
PremarinEstrogens, Conjugated12$5,755
Testosterone36$5,552
Alfuzosin Hcl ErAlfuzosin Hcl265$5,068
Doxazosin Mesylate379$4,405
Tolterodine Tartrate109$3,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$679$421,479227 claims
AbbVieLupron Depot$564$183,07720 claims
Johnson & JohnsonErleada$1,241$167,54812 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$455$114,450132 claims
Tolmar Pharmaceuticals, Inc.Eligard$89$53,09728 claims
PfizerPremarin$378$5,75512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.

Other urology in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →